Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited (TLX) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · TLX · as of Mar 31, 2025
Ownership Breakdown
6
Institutional Holders
▲ 5 vs Q4
$798,562
Total Inst. Value
▲ $741,120 vs Q4
338.78M
Shares Outstanding
freeFloat 80.51%
47,647
13F Shares Held
▲ 43,917 vs Q4
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
TLX largest shareholders · institutional ownership
Q1 2025 · SEC 13F
Showing top 6 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
ABC ARBITRAGE SA pharmaceutical preparations | 26.9K | 0.81% | 0.81% | $451.50M | May 9, 2025 | NEW |
PRIVATE ADVISOR GROUP, LLC pharmaceutical preparations | 10.1K | 0.31% | 0.31% | $169.95M | May 5, 2025 | NEW |
MORGAN STANLEY pharmaceutical preparations | 5.6K | 0.17% | 0.17% | $94.43M | May 15, 2025 | NEW |
UBS GROUP AG pharmaceutical preparations | 3.7K | 0.11% | 0.11% | $61.19M | May 13, 2025 | ▼ 79 |
RHUMBLINE ADVISERS pharmaceutical preparations | 1.1K | 0.03% | 0.03% | $19.20M | May 29, 2025 | NEW |
EVERSOURCE WEALTH ADVISORS, LLC pharmaceutical preparations | 137 | 0.00% | 0.00% | $2.30M | May 13, 2025 | NEW |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q1 2025 vs prior quarter
Q1 2025
0
Increased
+0 shares5
New Positions
first time holders1
Decreased
−79 shares0
Sold Out
fully exitedNet shares change (top 50)
79
+0 / −79
Net new holders
+4
5 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
TLX insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
0
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Behrenbruch Christian MD & Group CEO | Apr 29, 2026 | Purchase | 33,435 | $14.87 | $497.2K | 20.74M | Form 4 ↗ |
Behrenbruch Christian MD & Group CEO | Apr 28, 2026 | Purchase | 34,500 | $14.48 | $499.6K | 20.71M | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Telix Pharmaceuticals Limited (TLX) is primarily owned by institutional investors, who hold approximately 0.0% of total shares outstanding. Company insiders own approximately 19.49%, while retail and public investors account for the remaining 80.49%.
The largest institutional shareholder of Telix Pharmaceuticals Limited is ABC ARBITRAGE SA, holding approximately 26,939 shares — equal to 0.81% of outstanding shares — as of March 31, 2025.
A total of 6 institutional investors currently hold TLX stock, with a combined institutional value of approximately $798,562 as of the most recent 13F filing period.
Frequently asked questions
TLX ownershipTelix Pharmaceuticals Limited (TLX) is primarily owned by institutional investors, who hold approximately 0.0% of shares. The largest shareholder is ABC ARBITRAGE SA with a 0.81% stake. Company insiders hold 19.49%. Data sourced from SEC Form 13F as of March 31, 2025.